Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
Belite Bio (NASDAQ: BLTE) will host a live webcast on March 2, 2026 at 4:30 p.m. ET to discuss preliminary, unaudited fourth quarter and full year 2025 financial results and provide a business update.
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE) will host a live webcast on March 2, 2026 at 4:30 p.m. ET to discuss preliminary, unaudited fourth quarter and full year 2025 financial results and provide a business update.
According to the company, the webcast link is available at the events page and a replay will be accessible for approximately 90 days after the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BLTE
On Feb 23, the day this news came out, BLTE closed 4.59% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- Webcast date
- March 2, 2026
- Scheduled earnings and business update webcast
- Webcast time ET
- 4:30 p.m. Eastern Time
- Start time for Q4 and FY 2025 discussion
- Webcast time PT
- 1:30 p.m. Pacific Time
- Corresponding Pacific Time for webcast
- Replay duration
- 90 days
- Replay availability after the webcast
Previous Earnings Reports
-
Q3 2025 results, DRAGON completion, financings and strong cash position.
-
Q2 2025 results, Breakthrough Therapy status and PHOENIX enrollment progress.
-
Q1 2025 results, DRAGON DSMB support and PHOENIX enrollment update.
-
FY 2024 results, cash/investments detail and Tinlarebant trial progress.
-
Q3 2024 results, DRAGON II dosing, PHOENIX enrollment and cash update.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 2, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2025.
Webcast Information
Date: Monday, March 2, 2026
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/547616305
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook,or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Sophie Hunt
belite@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.